Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 23

HOS-112115 · Präparat HOS-093615

The increase in progestin exposure may lead to related side effects (e.g., insulin resistance, dyslipidemia, acne and spotting), thus possibly affecting the compliance. LIPID-MODIFYING AGENTS HMG-CoA reductase inhibitors Simvastatin Simvastatin and lovastatin are highly Co-administration of simvastatin or Lovastatin dependent on CYP3A4 for their lovastatin with REYATAZ is metabolism and co-administration with contraindicated due to an increased REYATAZ may result in increased risk of myopathy including concentrations. rhabdomyolysis (see section 4.3). Atorvastatin The risk of myopathy including Co-administration of atorvastatin rhabdomyolysis may also be increased with REYATAZ is not with atorvastatin, which is also recommended. If the use of metabolised by CYP3A4. atorvastatin is considered strictly necessary, the lowest possible dose of atorvastatin should be administered with careful safety monitoring (see section 4.4). Pravastatin Although not studied, there is a potential Caution should be exercised. Fluvastatin for an increase in pravastatin or fluvastatin exposure when co-administered with protease inhibitors. Pravastatin is not metabolised by CYP3A4. Fluvastatin is partially metabolised by CYP2C9. Other lipid-modifying agents Lomitapide Lomitapide is highly dependent on Co-administration of lomitapide CYP3A4 for metabolism and co- and REYATAZ with ritonavir is administration with REYATAZ with contraindicated due to a potential ritonavir may result in increased risk of markedly increased concentrations. transaminase levels and hepatotoxicity (see section 4.3). INHALED BETA AGONISTS Salmeterol Co-administration with REYATAZ may Co-administration of salmeterol result in increased concentrations of with REYATAZ is not salmeterol and an increase in salmeterol- recommended (see section 4.4). associated adverse events.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) lovastatin (HOS-086157) atorvastatin (HOS-086304) lomitapide (HOS-086160) simvastatin (HOS-086158) fluvastatin (HOS-086305) salmeterol (HOS-086285) lead (HOS-085592) ritonavir (HOS-084521) pravastatin (HOS-086306)